NCT05660538: A reported trial by Vertex Pharmaceuticals Incorporated
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05660538 |
|---|---|
| Title | A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Diabetic Peripheral Neuropathy |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 20, 2022 |
| Completion date | Oct. 12, 2023 |
| Required reporting date | Oct. 12, 2026, midnight |
| Actual reporting date | June 13, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |